Antifungal pre-emptive strategy for high-risk neutropenic patients: why the story is still ongoing

Area of Science:

• Hematology
• Infectious Diseases
• Oncology

Background:

• Neutropenic patients with hematologic malignancies face a high risk of invasive fungal disease (IFD).
• Early IFD diagnosis is challenging, leading to historical empirical antifungal treatment strategies.
• Modern imaging and biomarkers have prompted a debate on the cost-effectiveness and safety of empirical versus pre-emptive antifungal approaches.

Purpose of the Study:

• To review the evolution of strategies for managing invasive fungal disease in neutropenic patients.
• To discuss the implementation of pre-emptive antifungal strategies in hematology wards.
• To evaluate the clinical pertinence and safety of different diagnostic and treatment approaches for IFD.

Main Methods:

• Review of historical unpowered studies on empirical antifungal treatment.
• Analysis of modern pre-emptive strategies based on lung imaging, galactomannan antigenaemia, and fungal PCR.
• Discussion of the integration of these strategies in clinical practice.

Main Results:

• Empirical antifungal treatment was historically suggested to reduce IFD risk.
• Pre-emptive strategies using imaging and biomarkers aim to restrict antifungal administration to high-risk patients.
• Most pre-emptive studies suggest a reduction in antifungal use and associated costs.

Conclusions:

• The optimal design and clinical pertinence of pre-emptive strategies for IFD in neutropenic patients are still under investigation.
• Implementation in hematology wards requires careful consideration of diagnostic tools and patient risk stratification.
• Balancing early diagnosis, treatment efficacy, and resource optimization remains a key challenge.